Corcept Therapeutics

Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)

Retrieved on: 
Monday, July 17, 2023

These patients also experienced improvements in key metabolic and lipid measures such as HOMA-IR, serum triglycerides and LDL.

Key Points: 
  • These patients also experienced improvements in key metabolic and lipid measures such as HOMA-IR, serum triglycerides and LDL.
  • “Miricorilant is highly active in the liver with a unique mechanism of action and holds great promise for the treatment of NASH,” said Naim Alkhouri, MD, FAASLD, Chief Medical Officer of Arizona Liver Health.
  • “The combination of liver fat reduction, improvement in metabolic and lipid measures and low adverse event rate is compelling.
  • Miricorilant has the potential to be a potent solution for the large patient population with NASH.”

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, May 3, 2023

Net income was $15.9 million in the first quarter of 2023 compared to $22.8 million in the same period last year.

Key Points: 
  • Net income was $15.9 million in the first quarter of 2023 compared to $22.8 million in the same period last year.
  • In April 2023, Corcept purchased 6.6 million shares of its common stock for $145.4 million.
  • “Korlym is an excellent treatment for patients with Cushing’s syndrome and there are many eligible patients who have yet to receive it.
  • Corcept holds patents directed to the composition of relacorilant and the use of cortisol modulators, including Korlym, in the treatment of patients with hypercortisolism.

Corcept Therapeutics Announces Final Results of Tender Offer

Retrieved on: 
Wednesday, April 5, 2023

In accordance with the terms and conditions of the Tender Offer, based on the final count, Corcept has accepted for purchase 6,610,369 shares of common stock at a purchase price of $22.00 per share, for an aggregate cost of $145,428,118, excluding fees, any excise taxes and expenses relating to the Tender Offer.

Key Points: 
  • In accordance with the terms and conditions of the Tender Offer, based on the final count, Corcept has accepted for purchase 6,610,369 shares of common stock at a purchase price of $22.00 per share, for an aggregate cost of $145,428,118, excluding fees, any excise taxes and expenses relating to the Tender Offer.
  • The number of shares that Corcept has accepted for purchase in the Tender Offer represents approximately 6 percent of the total number of shares of common stock outstanding as of March 31, 2023.
  • Corcept had 101,545,296 shares of common stock outstanding following payment for the shares of common stock purchased in the Tender Offer.
  • This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any securities of Corcept.

Corcept Therapeutics Announces Preliminary Results of Tender Offer

Retrieved on: 
Monday, April 3, 2023

In accordance with the terms and conditions of the Tender Offer, based on these preliminary results, Corcept expects to purchase 6,630,151 shares of common stock at a purchase price of $22.00 per share, for an aggregate cost of $145,863,322, excluding fees, any excise taxes and expenses relating to the Tender Offer.

Key Points: 
  • In accordance with the terms and conditions of the Tender Offer, based on these preliminary results, Corcept expects to purchase 6,630,151 shares of common stock at a purchase price of $22.00 per share, for an aggregate cost of $145,863,322, excluding fees, any excise taxes and expenses relating to the Tender Offer.
  • The number of shares that Corcept expects to purchase in the Tender Offer represents approximately 6 percent of the total number of shares of common stock outstanding as of March 30, 2023.
  • Corcept expects to have 101,435,180 shares of common stock outstanding immediately following payment for the shares of common stock purchased in the Tender Offer.
  • This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any securities of Corcept.

Corcept Therapeutics Initiates CATALYST Clinical Trial

Retrieved on: 
Tuesday, March 28, 2023

“We are excited that our CATALYST trial is now open,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.

Key Points: 
  • “We are excited that our CATALYST trial is now open,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.
  • The most prominent diabetologists in the United States helped us design and are participating in CATALYST, which will be the largest study of its kind ever to be conducted.
  • Data from CATALYST will enable physicians to better identify and care for these patients.
  • Corcept holds patents directed to the composition of relacorilant and the use of cortisol modulators, including Korlym, in the treatment of patients with hypercortisolism.

Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock

Retrieved on: 
Monday, March 6, 2023

The closing price of the Shares on The Nasdaq Stock Market on March 3, 2023, the last full trading day before the start of the tender offer, was $19.20 per Share.

Key Points: 
  • The closing price of the Shares on The Nasdaq Stock Market on March 3, 2023, the last full trading day before the start of the tender offer, was $19.20 per Share.
  • The tender offer is scheduled to expire one minute after 11:59 P.M., New York City Time, March 31, 2023, unless the offer is extended or terminated.
  • The tender offer is also subject to terms and conditions, which are described in detail in the offer to purchase.
  • King & Co., Inc. is serving as the information agent for the tender offer and Continental Stock Transfer & Trust Company is serving as the depositary.

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 28, 2023

Net income was $16.6 million in the fourth quarter of 2022, compared to $32.1 million in the fourth quarter of 2021.

Key Points: 
  • Net income was $16.6 million in the fourth quarter of 2022, compared to $32.1 million in the fourth quarter of 2021.
  • Cash and investments of $436.6 million at December 31, 2022 compared to $335.8 million at December 31, 2021.
  • We are providing 2023 revenue guidance of $430 - $450 million,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.
  • Corcept holds patents directed to the composition of relacorilant and the use of cortisol modulators, including Korlym, in the treatment of patients with hypercortisolism.

Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation

Retrieved on: 
Monday, February 13, 2023

MENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has reached a preliminary settlement of all claims in the purported securities class action against Corcept and certain of its executive officers captioned Melucci v. Corcept Therapeutics Incorporated, et al., Case No.

Key Points: 
  • MENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has reached a preliminary settlement of all claims in the purported securities class action against Corcept and certain of its executive officers captioned Melucci v. Corcept Therapeutics Incorporated, et al., Case No.
  • 5:19-cv-01372-LHK, which was pending in the United States District Court for the Northern District of California.
  • Under the proposed settlement, Corcept has agreed to make a one-time payment of $14.0 million, which will be covered in full by Corcept’s insurers.

Corcept Therapeutics Inc. Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Thursday, December 29, 2022

LOS ANGELES, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Corcept Therapeutics Inc. (“Corcept” or the “Company”) (NASDAQ: CORT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Key Points: 
  • LOS ANGELES, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Corcept Therapeutics Inc. (“Corcept” or the “Company”) (NASDAQ: CORT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 310-692-8883 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

EQUITY ALERT: Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation – CORT

Retrieved on: 
Wednesday, December 28, 2022

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT).

Key Points: 
  • WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT).
  • The Rosen Law firm is preparing a class action seeking recovery of investor losses.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.